BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Active, not recruiting · NCT05558982 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Active, not recruiting | Phase 2 | 2026-09-14 | NCT05558982 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioXcel Therapeutics Inc | 4 |
| Georgetown University | 73 |
| Merck Sharp & Dohme LLC | 650 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C. | United States | 14 |